[1] Ross R. At herosclerosis 2 an inflammatory disease [J] . N Engl J Med, 1999,340 (2):B115-126.
[2] Koenig W. Inflammation and coronary heart disease:a nover 2 view [J]. Cardiol Rev,2001,9 (1):31-35.
[3] Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase,stromelysin, and tissue factor[J]. Circulation,1997,96: 396-399.
[4] Karpsas M, Hsu YM, Wang JH, et al. A crystal structure of an extracellular fragment of human CD40 ligand[J]. Structure,1995,3:1031-1039.
[5] Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and itsligand[J]. Annu Rev Immunol, 1994, 12: 881 - 922.
[6] Gerritse K, Laman JD, Noelle RJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis[J]. J Proc Natl Acad Sci USA,2000,473(2):149-159.
[7] Szabolcs MJ, Cannon PJ, Thienel U, et al. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated Coronary artery disease[J]. J Virchows Arch, 2000, 437(2):149-159.
[8] Ross R. Atherosclerosis an inflammation disease[J]. J N Engl Med,1999,340:115-126.
[9] Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages :Implication for CD40-CD40 ligand signaling in atherosclerosis[J]. J Proc Natl Acad Sci USA,1997,94: 1931-1936.
[10] 严金川,吴宗贵,仲人前,等.CD40-CD40L共同表达于人内皮细胞及人动脉粥样斑块中[J].中国病理生理杂志,2002,19(8):1021-1024.
体育论文发表
[11] Davies MJ, Gordon JL, Gearing AJ, et a1.The expression of the adhesion molecules ICAM-1,VCAM-1,PECAM, and E-selectin in human atherosclerosis[J]. J Pathol,1993, I 71(3): 223-229.
[12] Bruemmer D, Riggers U, Holzmeister J, et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions[J]. J Am J Cardiol, 2001,87(1):21-27.
[13] Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis[J]. Am J Cardiovasc Drugs, 2005,5(6):399-408.
[14] Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease[J]. Circulation, 2002,106(8):981-986.
[15] Falk E. Morphologic of feature coronary syndromes[J]. Am J Cardio,1989, 63(10):114E-120E.
[16] Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor[J]. Circulation,1997,96: 396-399.
[17] Schonbeck U, Mach F, Sukhoa GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth cells by T lymphocytes: a role for CD40 signaling in plaque rupture[J]. Circ Res,1997,81:448-454.
[18] Lutgens E, Cleutiens KB, Heenman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype[J]. Proc Natl Acad Sci USA, 2000,97: 7464-7469.
[19] Henn V, Slupsky J, Grafe M, et al. CD40 ligand on activated platelets triggers an infammatory reaction of endothelial cell[J]. J Nature,1998,391(6667):591-594.
[20] Lutgens E,Daemen MJ.CD40-CD40L interacting in atherosclerosis[J].Trends Cardiovasc Med, 2002,12:27-32.
[21] Aggarwal A, Schneider DJ, Terrien EF, et al. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques[J]. Am J Cardiol, 2004,93(1):6-9.
[22] Yan JC, Zhu J, Gao L, et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes[J]. Clin Chim Acta, 2004, 343 (1-2): 155-159.